David M. Clarke

Personal Home Page

http://biochemistry.utoronto.ca/clarke/bch.html

Articles in Scholarly Journals [Incomplete List]

  1. Chemical and pharmacological chaperones as new therapeutic agents
    Expert Reviews in Molecular Medicine, vol. 9, no. 16, 2007
  2. Nucleotide Binding, ATP Hydrolysis, and Mutation of the Catalytic Carboxylates of Human P-Glycoprotein Cause Distinct Conformational Changes in the Transmembrane Segments
    Biochemistry, vol. 46, no. 32, pp. 9328–9336, 2007
  3. Additive effect of multiple pharmacological chaperones on maturation of CFTR processing mutants
    Biochemical Journal, vol. 406, no. 2, p. 257, 2007
  4. Correctors Promote Maturation of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)-processing Mutants by Binding to the Protein
    Journal of Biological Chemistry, vol. 282, no. 46, pp. 33247–33251, 2007
  5. Suppressor Mutations in the Transmembrane Segments of P-glycoprotein Promote Maturation of Processing Mutants and Disrupt a Subset of Drug-binding Sites
    Journal of Biological Chemistry, vol. 282, no. 44, pp. 32043–32052, 2007
  6. Insertion of an Arginine Residue into the Transmembrane Segments Corrects Protein Misfolding
    Journal of Biological Chemistry, vol. 281, no. 40, pp. 29436–29440, 2006
  7. Using a cysteine-less mutant to provide insight into the structure and mechanism of CFTR
    The Journal of Physiology, vol. 572, no. 2, pp. 312–312, 2006
  8. Specific Rescue of CFTR Processing Mutants Using Pharmacological Chaperones
    Molecular Pharmacology, 2006
  9. Modulating the Folding of P-Glycoprotein and Cystic Fibrosis Transmembrane Conductance Regulator Truncation Mutants with Pharmacological Chaperones
    Molecular Pharmacology, vol. 71, no. 3, pp. 751–758, 2006
  10. Transmembrane segment 1 of human P-glycoprotein contributes to the drug-binding pocket
    Biochemical Journal, vol. 396, no. 3, p. 537, 2006
  11. The chemical chaperone CFcor-325 repairs folding defects in the transmembrane domains of CFTR-processing mutants
    Biochemical Journal, vol. 395, no. 3, p. 537, 2006
  12. Transmembrane segment 7 of human P-glycoprotein forms part of the drug-binding pocket
    Biochemical Journal, vol. 399, no. 2, p. 351, 2006
  13. Molecular Pharmaceutics, vol. 2, no. 5, pp. 407–413, 2005
  14. Biochemistry, vol. 44, no. 30, pp. 10250–10258, 2005
  15. Do drug substrates enter the common drug-binding pocket of P-glycoprotein through ?gates??
    Biochemical and Biophysical Research Communications, vol. 329, no. 2, pp. 419–422, 2005
  16. Recent Progress in Understanding the Mechanism of P-Glycoprotein-mediated Drug Efflux
    Journal of Membrane Biology, vol. 206, no. 3, pp. 173–185, 2005
  17. Rescue of Folding Defects in ABC Transporters Using Pharmacological Chaperones
    Journal of Bioenergetics and Biomembranes, vol. 37, no. 6, pp. 501–507, 2005
  18. Thapsigargin or curcumin does not promote maturation of processing mutants of the ABC transporters, CFTR, and P-glycoprotein
    Biochemical and Biophysical Research Communications, vol. 325, no. 2, pp. 580–585, 2004
  19. Biochemistry, vol. 43, no. 38, pp. 12081–12089, 2004
  20. Val133 and Cys137 in Transmembrane Segment 2 Are Close to Arg935 and Gly939 in Transmembrane Segment 11 of Human P-glycoprotein
    Journal of Biological Chemistry, vol. 279, no. 18, pp. 18232–18238, 2004
  21. Processing Mutations Located throughout the Human Multidrug Resistance P-glycoprotein Disrupt Interactions between the Nucleotide Binding Domains
    Journal of Biological Chemistry, vol. 279, no. 37, pp. 38395–38401, 2004
  22. The  F508 Mutation Disrupts Packing of the Transmembrane Segments of the Cystic Fibrosis Transmembrane Conductance Regulator
    Journal of Biological Chemistry, vol. 279, no. 38, pp. 39620–39627, 2004
  23. The Dileucine Motif at the COOH Terminus of Human Multidrug Resistance P-glycoprotein Is Important for Folding but Not Activity
    Journal of Biological Chemistry, vol. 280, no. 4, pp. 2522–2528, 2004
  24. Molecular Pharmaceutics, vol. 1, no. 6, pp. 426–433, 2004
  25. Substrate-induced Conformational Changes in the Transmembrane Segments of Human P-glycoprotein. DIRECT EVIDENCE FOR THE SUBSTRATE-INDUCED FIT MECHANISM FOR DRUG BINDING
    Journal of Biological Chemistry, vol. 278, no. 16, pp. 13603–13606, 2003
  26. Permanent Activation of the Human P-glycoprotein by Covalent Modification of a Residue in the Drug-binding Site
    Journal of Biological Chemistry, vol. 278, no. 23, pp. 20449–20452, 2003
  27. Drug Binding in Human P-glycoprotein Causes Conformational Changes in Both Nucleotide-binding Domains
    Journal of Biological Chemistry, vol. 278, no. 3, pp. 1575–1578, 2003
  28. Simultaneous Binding of Two Different Drugs in the Binding Pocket of the Human Multidrug Resistance P-glycoprotein
    Journal of Biological Chemistry, vol. 278, no. 41, pp. 39706–39710, 2003
  29. Methanethiosulfonate Derivatives of Rhodamine and Verapamil Activate Human P-glycoprotein at Different Sites
    Journal of Biological Chemistry, vol. 278, no. 50, pp. 50136–50141, 2003
  30. Disulfide Cross-linking Analysis Shows That Transmembrane Segments 5 and 8 of Human P-glycoprotein Are Close Together on the Cytoplasmic Side of the Membrane
    Journal of Biological Chemistry, vol. 279, no. 9, pp. 7692–7697, 2003
  31. Location of the Rhodamine-binding Site in the Human Multidrug Resistance P-glycoprotein
    Journal of Biological Chemistry, vol. 277, no. 46, pp. 44332–44338, 2002
  32. Introduction of the Most Common Cystic Fibrosis Mutation (Delta F508) into Human P-glycoprotein Disrupts Packing of the Transmembrane Segments
    Journal of Biological Chemistry, vol. 277, no. 31, pp. 27585–27588, 2002
  33. The "LSGGQ" Motif in Each Nucleotide-binding Domain of Human P-glycoprotein Is Adjacent to the Opposing Walker A Sequence
    Journal of Biological Chemistry, vol. 277, no. 44, pp. 41303–41306, 2002
  34. Vanadate trapping of nucleotide at the ATP-binding sites of human multidrug resistance P-glycoprotein exposes different residues to the drug-binding site
    Proceedings of the National Academy of Sciences, vol. 99, no. 6, pp. 3511–3516, 2002
  35. BMC Biochemistry, vol. 3, no. 1, p. 1, 2002
  36. BMC Biochemistry, vol. 3, no. 1, p. 29, 2002
  37. Determining the Dimensions of the Drug-binding Domain of Human P-glycoprotein Using Thiol Cross-linking Compounds as Molecular Rulers
    Journal of Biological Chemistry, vol. 276, no. 40, pp. 36877–36880, 2001
  38. Defining the Drug-binding Site in the Human Multidrug Resistance P-glycoprotein Using a Methanethiosulfonate Analog of Verapamil, MTS-verapamil
    Journal of Biological Chemistry, vol. 276, no. 18, pp. 14972–14979, 2001
  39. Cross-linking of Human Multidrug Resistance P-glycoprotein by the Substrate, Tris-(2-maleimidoethyl)amine, Is Altered by ATP Hydrolysis. EVIDENCE FOR ROTATION OF A TRANSMEMBRANE HELIX
    Journal of Biological Chemistry, vol. 276, no. 34, pp. 31800–31805, 2001
  40. Identification of Residues within the Drug-binding Domain of the Human Multidrug Resistance P-glycoprotein by Cysteine-scanning Mutagenesis and Reaction with Dibromobimane
    Journal of Biological Chemistry, vol. 275, no. 50, pp. 39272–39278, 2000
  41. The Packing of the Transmembrane Segments of Human Multidrug Resistance P-glycoprotein Is Revealed by Disulfide Cross-linking Analysis
    Journal of Biological Chemistry, vol. 275, no. 8, pp. 5253–5256, 2000
  42. Drug-stimulated ATPase Activity of Human P-glycoprotein Is Blocked by Disulfide Cross-linking between the Nucleotide-binding Sites
    Journal of Biological Chemistry, vol. 275, no. 26, pp. 19435–19438, 2000
  43. Biochemistry, vol. 39, no. 13, pp. 3797–3803, 2000
  44. Blockage of Drug Resistance In Vitro by Disulfiram, a Drug Used to Treat Alcoholism
    Journal of the National Cancer Institute, vol. 92, no. 11, pp. 898–902, 2000
  45. Biochemistry, vol. 38, no. 16, pp. 5124–5129, 1999
  46. Influence of phosphorylation by protein kinase A on CFTR at the cell surface and endoplasmic reticulum
    Biochimica et Biophysica Acta (BBA) - Biomembranes, vol. 1461, no. 2, pp. 275–283, 1999
  47. Determining the structure and mechanism of the human multidrug resistance P-glycoprotein using cysteine-scanning mutagenesis and thiol-modification techniques
    Biochimica et Biophysica Acta (BBA) - Biomembranes, vol. 1461, no. 2, pp. 315–325, 1999
  48. The Transmembrane Domains of the Human Multidrug Resistance P-glycoprotein Are Sufficient to Mediate Drug Binding and Trafficking to the Cell Surface
    Journal of Biological Chemistry, vol. 274, no. 35, pp. 24759–24765, 1999
  49. Identification of Residues in the Drug-binding Domain of Human P-glycoprotein. ANALYSIS OF TRANSMEMBRANE SEGMENT 11 BY CYSTEINE-SCANNING MUTAGENESIS AND INHIBITION BY DIBROMOBIMANE
    Journal of Biological Chemistry, vol. 274, no. 50, pp. 35388–35392, 1999
  50. Molecular dissection of the human multidrug resistance P-glycoprotein
    Biochemistry and Cell Biology, vol. 77, no. 1, pp. 11–23, 1999
  51. Superfolding of the Partially Unfolded Core-glycosylated Intermediate of Human P-glycoprotein into the Mature Enzyme Is Promoted by Substrate-induced Transmembrane Domain Interactions
    Journal of Biological Chemistry, vol. 273, no. 24, pp. 14671–14674, 1998
  52. Quality Control by Proteases in the Endoplasmic Reticulum. REMOVAL OF A PROTEASE-SENSITIVE SITE ENHANCES EXPRESSION OF HUMAN P-GLYCOPROTEIN
    Journal of Biological Chemistry, vol. 273, no. 49, pp. 32373–32376, 1998
  53. Nonylphenol Ethoxylates, but Not Nonylphenol, Are Substrates of the Human Multidrug Resistance P-glycoprotein
    Biochemical and Biophysical Research Communications, vol. 247, no. 2, pp. 478–480, 1998
  54. Biochemistry, vol. 36, no. 39, pp. 11966–11974, 1997
  55. Journal of Bioenergetics and Biomembranes, vol. 29, no. 5, pp. 429–442, 1997
  56. Correction of Defective Protein Kinesis of Human P-glycoprotein Mutants by Substrates and Modulators
    Journal of Biological Chemistry, vol. 272, no. 2, pp. 709–712, 1997
  57. Drug-stimulated ATPase Activity of Human P-glycoprotein Requires Movement between Transmembrane Segments 6 and 12
    Journal of Biological Chemistry, vol. 272, no. 34, pp. 20986–20989, 1997
  58. Identification of Residues in the Drug-binding Site of Human P-glycoprotein Using a Thiol-reactive Substrate
    Journal of Biological Chemistry, vol. 272, no. 51, pp. 31945–31948, 1997
  59. Disease-associated Mutations in the Fourth Cytoplasmic Loop of Cystic Fibrosis Transmembrane Conductance Regulator Compromise Biosynthetic Processing and Chloride Channel Activity
    Journal of Biological Chemistry, vol. 271, no. 25, pp. 15139–15145, 1996
  60. Mutational Analysis of the Predicted First Transmembrane Segment of Each Homologous Half of Human P-glycoprotein Suggests That They Are Symmetrically Arranged in the Membrane
    Journal of Biological Chemistry, vol. 271, no. 26, pp. 15414–15419, 1996
  61. Inhibition of Oxidative Cross-linking between Engineered Cysteine Residues at Positions 332in Predicted Transmembrane Segments (TM) 6and 975in Predicted TM12 of Human P-glycoprotein by Drug Substrates
    Journal of Biological Chemistry, vol. 271, no. 44, pp. 27482–27487, 1996
  62. The Minimum Functional Unit of Human P-glycoprotein Appears to be a Monomer
    Journal of Biological Chemistry, vol. 271, no. 44, pp. 27488–27492, 1996
  63. Cytoplasmic Loop Three of Cystic Fibrosis Transmembrane Conductance Regulator Contributes to Regulation of Chloride Channel Activity
    Journal of Biological Chemistry, vol. 271, no. 44, pp. 27493–27499, 1996
  64. Membrane Topology of a Cysteine-less Mutant of Human P-glycoprotein
    Journal of Biological Chemistry, vol. 270, no. 2, pp. 843–848, 1995
  65. Expression of a Functionally Active Human Renal Sodium-Calcium Exchanger Lacking a Signal Sequence
    Journal of Biological Chemistry, vol. 270, no. 33, pp. 19345–19350, 1995
  66. Rapid Purification of Human P-glycoprotein Mutants Expressed Transiently in HEK 293 Cells by Nickel-Chelate Chromatography and Characterization of their Drug-stimulated ATPase Activities
    Journal of Biological Chemistry, vol. 270, no. 37, pp. 21449–21452, 1995
  67. P-glycoprotein
    Journal of Biological Chemistry, vol. 270, no. 37, pp. 21839–21844, 1995
  68. Covalent Modification of Human P-glycoprotein Mutants Containing a Single Cysteine in Either Nucleotide-binding Fold Abolishes Drug-stimulated ATPase Activity
    Journal of Biological Chemistry, vol. 270, no. 39, pp. 22957–22961, 1995
  69. Biochemistry, vol. 33, no. 47, pp. 14049–14057, 1994
  70. Deletion of NH2- and COOH-terminal sequences destroys function of the Ca2+ ATPase of rabbit fast-twitch skeletal muscle sarcoplasmic reticulum
    FEBS Letters, vol. 336, no. 1, pp. 168–170, 1993
  71. Expression and mutation of Ca2+ ATPases of the sarcoplasmic reticulum
    Cell Motility and the Cytoskeleton, vol. 14, no. 1, pp. 26–34, 1989
  72. Location of high affinity Ca2 +-binding sites within the predicted transmembrahe domain of the sarco-plasmic reticulum Ca2+-ATPase
    Nature, vol. 339, no. 6224, Article ID 339476a0, 2 pages, 1989
  73. Expression of rubella virus cDNA coding for the structural proteins
    Gene, vol. 65, no. 1, pp. 23–30, 1988
  74. Detection of antibodies to individual proteins of rubella virus
    Journal of Virological Methods, vol. 13, no. 2, pp. 149–159, 1986
  75. Isolation of a fourth cysteinyl-containing peptide of the a-subunit of the F1 ATPase from Escherichia coli necessitates revision of the DNA sequence
    FEBS Letters, vol. 197, no. 1-2, pp. 121–124, 1986
  76. Nucleotide sequence of the pntA and pntB genes encoding the pyridine nucleotide transhydrogenase of Escherichia coli
    European Journal of Biochemistry, vol. 158, no. 3, pp. 647–653, 1986
  77. Purification and properties of reconstitutively active nicotinamide nucleotide transhydrogenase of Escherichia coli
    European Journal of Biochemistry, vol. 149, no. 3, pp. 517–523, 1985